New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:33 EDTAZN, BMYAstraZeneca completes acquisition of Bristol-Myers assets
AstraZeneca (AZN) announced that it completed its acquisition of the entirety of Bristol-Myers Squibb’s (BMY) interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialization of the diabetes business, which in the U.S. includes ONGLYZA, KOMBIGLYZE XR, FARXIGA, BYETTA, BYDUREON, Symlin and the investigational agent metreleptin. On completion of the acquisition, AstraZeneca paid Bristol-Myers Squibb $2.7B for initial consideration. AstraZeneca has also agreed to pay up to $1.4B in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600M of which relates to the approval of FARXIGA in the U.S. In addition, AstraZeneca may make payments up to $225M when certain assets are subsequently transferred.
News For AZN;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
07:03 EDTBMYBristol-Myers enters agreement to acquire F-star Alpha, rights to FS102
October 27, 2014
20:54 EDTAZN, BMYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
15:18 EDTAZNEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
07:29 EDTAZNWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
07:22 EDTAZNAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
16:02 EDTBMYOptions Update; October 24, 2014
Subscribe for More Information
11:15 EDTBMYBristol-Myers says has capacity for large deal
Subscribe for More Information
10:42 EDTBMYBristol-Myers sees coming in closer to high end of FY14 EPS guidance
Subscribe for More Information
10:10 EDTBMYBristol-Myers to host conference call
Conference call to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) will be held on October 31 at 2:30 pm. Webcast Link
07:35 EDTBMYBristol-Myers reports Q3 Eliquis revenue $216M
Reports Q3 Baraclude revenue $325M, Sprycel revenue $385M, Yervoy revenue $350M. Reports Q3 Abilify revenue $449M, Orencia revenue $444M.
07:33 EDTBMYBristol-Myers confirms FY14 adjusted EPS view $1.70-$1.80, consensus $1.78
Cuts FY14 GAAP EPS view to $1.15-$1.25 from $1.50-$1.60. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. Sees FY14 worldwide revenue $15.2B-$15.8B, consensus $15.58B. Also sees: Full-year gross margin as a percentage of revenues between 75% and 76%. Advertising and promotion expense decreasing in the mid-teen-digit range. Marketing, sales and administrative expenses decreasing in the mid-single-digit range. Research and development expenses growing in the mid-single-digit range. An effective tax rate of 19% - 20%.
07:31 EDTBMYBristol-Myers reports Q3 adjusted EPS 45c, consensus 42c
Subscribe for More Information
06:49 EDTAZNPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
October 23, 2014
15:39 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
October 22, 2014
07:35 EDTAZNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
07:15 EDTBMY, AZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTBMY, AZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use